Morgan Stanley
- SEC CIK
- 0000895421
- Latest filing
- Aug 13, 2026
ALZN holding history
Alzamend Neuro, Inc. in every 13F filed by Morgan Stanley, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ALZN overviewAll 13F holders of ALZNFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 17
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −18,000−100.0% | Sold out | Holders |
| Q1 2026 | 18,000 | $19.1K | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2025 | 18,000 | $32.8K | <0.1% | +18,000 | New | Holders |
| Q2 2025 | 0 | $0 | 0.0% | −3−100.0% | Sold out | Holders |
| Q1 2025 | 3 | $3 | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2024 | 3 | $3 | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2024 | 3 | $5 | <0.1% | −0−9.1% | ReducedConverted for a 1-for-10 split | Holders |
| Q2 2024 | 33 | $13 | <0.1% | 00.0% | Unchanged | Holders |
| Q1 2024 | 33 | $33 | <0.1% | 00.0% | Unchanged | Holders |
| Q4 2023 | 33 | $29 | <0.1% | −0−1.0% | ReducedConverted for a 1-for-15 split | Holders |
| Q3 2023 | 500 | $119 | <0.1% | 00.0% | Unchanged | Holders |
| Q2 2023 | 500 | $255 | <0.1% | −2,465−83.1% | Reduced | Holders |
| Q1 2023 | 2,965 | $1.26K | <0.1% | −3,700−55.5% | Reduced | Holders |
| Q4 2022 | 6,665 | $3.77K | <0.1% | +2,965+80.1% | Added | Holders |
| Q3 2022 | 3,700 | $4.00K | <0.1% | −200−5.1% | Reduced | Holders |
| Q2 2022 | 3,900 | $3.00K | <0.1% | +100+2.6% | Added | Holders |
| Q1 2022 | 3,800 | $5.00K | <0.1% | +3,800 | New | Holders |
| Q4 2021 | 0 | $0 | 0.0% | −326−100.0% | Sold out | Holders |
| Q3 2021 | 326 | $1.00K | <0.1% | +67+25.9% | Added | Holders |
| Q2 2021 | 259 | $2.00K | <0.1% | +259 | New | Holders |